ResearchRSS4 days ago
Researchers in China used artificial intelligence to study the genes involved in pulmonary arterial hypertension (PAH), a serious condition where blood vessels in the lungs become narrowed and stiff. They identified two genes called ATP1B1 and HP that appear to be important in causing PAH. These genes could potentially become targets for new treatments in the future.
WHY IT MATTERSIf ATP1B1 and HP prove to be valid therapeutic targets, they could lead to new treatment options for PAH patients who currently have limited medication choices.
ResearchRSSMay 6
Scientists in China discovered four genes—COL1A1, MYL9, COL1A2, and TPM2—that may be responsible for causing idiopathic pulmonary arterial hypertension (PAH), a rare lung disease where blood vessels in the lungs become abnormally narrow and stiff. They used computer analysis to identify these genes and then tested their findings in cells and animals to confirm the results. These genes could become targets for new treatments in the future.
WHY IT MATTERSIdentifying these four driver genes gives researchers specific targets to develop new treatments for idiopathic PAH, a disease with limited treatment options and poor survival rates if left untreated.
ResearchRSSMay 4
Researchers in China created a new drug called CPD1 that belongs to a class of medications called PDE5 inhibitors, which are already used to treat high blood pressure in the lungs (pulmonary arterial hypertension). In early testing on rats with this condition, CPD1 reduced disease severity and helped scientists understand how the drug works at a molecular level.
WHY IT MATTERSThis research identifies a potential new treatment option for PAH patients, though it remains in early preclinical stages and is years away from human testing or availability.
ResearchPUBMEDMay 1
Researchers studied patent applications from China between 1995 and 2023 to understand how many new orphan drugs (medicines for rare diseases) are being developed there. They found that China filed 58% more patent applications for rare disease treatments between 2018 and 2023, with most focus on cancer and brain diseases. This shows China is investing more in rare disease research, especially after new government policies were put in place.
WHY IT MATTERSPatients with rare diseases in China and globally benefit when more countries invest in orphan drug development, as increased competition and innovation can lead to more treatment options and potentially lower costs.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.
ResearchPUBMEDMar 26
Researchers in China studied 26 children and young adults (average age 8 years old) who had a rare cancer called rhabdomyosarcoma that started in the female reproductive organs. They tracked these patients for an average of nearly 5 years to see how well different treatments worked. This study helps doctors understand the best ways to treat this uncommon type of cancer in girls and young women.
WHY IT MATTERSThis is the first large study from China showing long-term survival rates for girls with genital rhabdomyosarcoma, which can help doctors worldwide improve treatment plans and give families more accurate information about what to expect.